Bicara Therapeutics BCAX Business Segments — Research
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's business segments — research.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's business segments — research?
- Bicara Therapeutics (BCAX) reported business segments — research of $601K in Q1 2026.
- How has Bicara Therapeutics's business segments — research changed year-over-year?
- Bicara Therapeutics's business segments — research increased by 8.1% year-over-year, from $556K to $601K.
- What is the long-term trend for Bicara Therapeutics's business segments — research?
- Over 2 years (2023 to 2025), Bicara Therapeutics's business segments — research has grown at a 50.1% compound annual growth rate (CAGR), from $1.39M to $3.12M.
- What does business segments — research mean?
- Refers to the foundational costs associated with early-stage scientific exploration and discovery efforts. This encompasses initial laboratory work and feasibility studies aimed at identifying and validating new therapeutic targets.